Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for rare diseases and oncology. The company's lead programs include AVTX-002 (anti-LIGHT antibody) for non-eosinophilic asthma and inflammatory diseases, and AVTX-007 (anti-IL-1β antibody) for inflammatory conditions. With minimal revenue, negative operating cash flow of approximately $10M annually, and a current ratio of 14.28x, the company is in cash-preservation mode while advancing clinical trials.
As a pre-revenue clinical-stage biotech, Avalo operates on a research-and-development model funded by equity raises and strategic partnerships. The company seeks to advance drug candidates through Phase 2/3 trials, then either commercialize independently or out-license to larger pharmaceutical partners for milestone payments and royalties. The 183% gross margin reflects accounting treatment of collaboration revenue against minimal direct costs. Value creation depends entirely on clinical trial success, regulatory approval probability, and partnership economics. Current burn rate suggests 3-4 years of runway at current cash levels.
Clinical trial data readouts for AVTX-002 and AVTX-007 (primary catalyst for 50%+ single-day moves)
FDA regulatory interactions including IND clearances, Fast Track designations, or Breakthrough Therapy status
Partnership announcements with Big Pharma for co-development or licensing deals (validates platform, provides non-dilutive funding)
Equity financing announcements and cash runway updates (dilution concerns drive 20-30% volatility)
Competitive clinical data from rival programs targeting similar pathways (anti-LIGHT, anti-IL-1β space)
Binary clinical trial risk: Single failed Phase 2/3 trial can render company value near-zero given concentrated pipeline (AVTX-002 and AVTX-007 represent substantially all enterprise value)
Regulatory pathway uncertainty for rare disease indications with limited precedent, requiring extensive FDA dialogue on endpoints and trial design
Reimbursement risk: Even with approval, payer coverage for rare disease therapies faces increasing scrutiny, particularly for conditions with existing treatment options
Large pharmaceutical companies developing competing anti-inflammatory biologics with superior resources for trial execution and commercialization infrastructure
Academic institutions and well-funded biotechs pursuing alternative mechanisms in the same disease indications, potentially achieving faster regulatory approval
Patent expiration risk on core intellectual property (typical biotech patents have 10-12 years of exclusivity remaining from filing), limiting commercial runway post-approval
Equity dilution risk: With $10M+ annual cash burn and no revenue, the company will require additional financing within 24-36 months, likely at dilutive terms given current market cap of $200M
Going concern risk if clinical trials fail or are delayed: Current cash runway assumes no major setbacks; trial holds or negative data could accelerate cash depletion
Warrant and option overhang: Clinical-stage biotechs typically have 15-25% fully-diluted share count above basic shares, creating downward pressure on stock price
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than consumer demand. However, economic downturns can impact: (1) ability to raise capital as risk appetite declines, (2) partnership deal flow as Big Pharma tightens M&A budgets, and (3) investor sentiment toward speculative growth stocks. The company's survival depends on access to capital markets, not economic cycles.
Rising interest rates negatively impact valuation through two mechanisms: (1) higher discount rates applied to distant future cash flows (biotech NPV models are extremely duration-sensitive with 8-12 year timelines to commercialization), and (2) reduced investor appetite for cash-burning growth stocks as risk-free alternatives become attractive. A 100bp rate increase can compress biotech multiples by 15-25%. Operationally, the company holds cash in short-term instruments, so rising rates modestly improve interest income but this is immaterial relative to burn rate.
Minimal - The company has zero debt (Debt/Equity: 0.00) and operates entirely on equity financing. Credit market conditions are irrelevant to operations but indirectly affect the biotech sector's ability to raise capital. Tight credit conditions can reduce crossover investor participation in biotech IPOs and follow-ons, making equity raises more dilutive.
growth/speculative - Attracts high-risk-tolerance investors seeking asymmetric returns from clinical trial success (potential 300-500% upside on positive data, 70-90% downside on failure). Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors with sector expertise. The 113.5% one-year return and 67.8% six-month return reflect momentum trading around clinical catalysts. Not suitable for income or value investors given zero revenue, negative cash flow, and binary risk profile.
high - Clinical-stage biotechs exhibit 60-100% annualized volatility driven by binary clinical events. The stock experiences 20-50% single-day moves on trial data releases. Beta to broader market is low (0.3-0.5) as stock-specific catalysts dominate, but correlation to biotech sector indices is high (0.7-0.8). Options market typically prices 80-120% implied volatility around known data readout dates.
